BB BIOTECH AG Thomas Egger, teg@te-communications.ch www.bbbiotech.com Company profile BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions. Disclaimer This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors. Composition of BB Biotech's portfolio as of December 31, 2020 (in % of securities, rounded values) Ionis Pharmaceuticals 10.4% Moderna 6.7% Neurocrine Biosciences 6.5% Argenx SE 6.1% Incyte 5.6% Vertex Pharmaceuticals 4.8% Alexion Pharmaceuticals 4.5% Arvinas 4.1% Fate Therapeutics 4.1% Agios Pharmaceuticals 4.0% Halozyme Therapeutics 3.8% Alnylam Pharmaceuticals 3.4% Crispr Therapeutics 3.1% Sage Therapeutics 3.0% Radius Health 3.0% Biogen 2.9% Myovant Sciences 2.9% Intra-Cellular Therapies 2.5% Macrogenics 2.5% Scholar Rock Holding 2.5% Esperion Therapeutics 2.3% Generation Bio Co. 1.5% Molecular Templates 1.3% Relay Therapeutics 1.3% Exelixis 1.3% Mersana Therapeutics 1.1% Nektar Therapeutics 1.0% Black Diamond Therapeutics 1.0% Beam Therapeutics 0.7% Kezar Life Sciences 0.5% Wave Life Sciences 0.5% Homology Medicines 0.4% Voyager Therapeutics 0.4% Cidara Therapeutics 0.1% Alder Biopharmaceuticals - CVR 0.1% Total securities CHF 3 954.7 mn Other assets CHF 8.4 mn Other payables CHF (75.6) mn Net Asset Value CHF 3 887.5 mn -----------------------------------------------------------------------------------------------------------------------
2021-01-22 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------
Language: English
Company: BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX
EQS News ID: 1162360
End of News DGAP News Service
=---------- (MORE TO FOLLOW) Dow Jones Newswires
January 22, 2021 01:06 ET (06:06 GMT)
